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Malignant Lymphomas: 
The term 'malignant lymphoma' embraces all neoplastic diseases that originates 
in the lymph nodes or extranodal lymphatic tissue. They comprise Hodgkin 
lymphoma, which is relatively uniform in histology, and the large 
heterogeneous category known as the non-Hodgkin lymphomas, which vary 
from highly proliferating and rapidly fatal disorders to indolent (although often 
incurable) malignancies that may be well tolerated for 10 to 20 years or more. 
It has been known for many years that non-Hodgkin lymphomas represent 
monoclonal expansions of B or T cells or natural killer cells (NK). Evidence of 
this comes from both expression of a single type of Immunoglobulin (Ig) on 
the cell surface and/or within the cytoplasm and also from studies of Ig or T-
cell receptor gene rearrangement. It's possible to find a normal counterpart for 
many types of non-Hodgkin lymphoma. The large number of these diseases 
reflects the rich diversity of much of the maturation stages and sub-populations 
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of reacting human lymphoid cells. The Reed-Sternberg cells characteristic of a 
Hodgkin lymphoma are also clonal in origin, deriving from B cells.  
Sometimes the difference between lymphomas, in which lymph node, spleen, 
or other solid tumor is present, and lymphoid leukemias (acute and chronic), 
with dominant bone marrow disease, is imprecise because lymphomas can be 
leukemic and leukemias can be lymphomatous (e.g., they can manifest as solid 
tumor deposits). A single lymphoproliferative disease can be categorized as 
two clinical manifestations, for example, chronic lymphocytic leukemia and 
small lymphocytic lymphoma merge into each other, their cell phenotypes and 
genotypes being identical. Also lymphoblastic lymphomas of precursor B or T 
cells are now classified with B-cells lineage acute lymphoblastic leukemia 
(ALL) or T-cell ALL, respectively, and treated as such. 
The frequencies of some types of non-Hodgkin lymphoma vary markedly 
between the different parts of the world. For example, two lymphoma 
categories that are common in Western countries, Hodgkin lymphoma and 
follicular lymphoma, are much rarer in Eastern and less developed countries, 
whereas large B-cell lymphoma and T-cell neoplasm are more frequent in the 
latter areas. Some subtypes of non-Hodgkin lymphoma that are only rarely 
seen in Western countries are found at much higher frequency elsewhere, and 
this may be partly accounted for by local patterns of exposure to viruses and 
other pathogens. In each of these instances the infectious agent presumably 
provides a stimulating effect on lymphoid cell growth, but how this interacts 
with other cellular mechanisms to induce neoplastic transformation is unclear. 
The molecular etiology of lymphomas has been shown by the study of 
chromosome alterations, and in many instances the consequences of these 
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alterations have been identified at the DNA level. Other diseases (e.g., mantle 
cell lymphoma, ALK positive, and anaplastic large cell lymphoma) are defined 
on the basis of genetic abnormality. In the past many large cell non-Hodgkin 
lymphomas were referred to as 'histiocytic', but it's now evident that the vast 
majority of neoplasm arising from the monocyte-phagocyte system manifest as 
leukemias. [1] 
The classification of the lymphomas has undergone significant new 
evaluations over the past 50 years. These changes have resulted from insights 
gained through the application of molecular and immunologic techniques and a 
better comprehension of the clinical aspects of lymphoma through advances in 
diagnosis, staging and treatment.  
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Classifying non-Hodgkin lymphoma (NHL) can be quite confusing because 
there are so many types and because several different systems have been used. 
The most recent system is the World Health Organization (WHO) classification 
(2008).  
 
WHO classification represents a significant achievement in terms of 
cooperation among pathologists, hematologists, and oncologists. Moreover, it 
recognizes, as in the REAL classification, that any classification system is an 
evolving process and should incorporate new data resulting from recent 
technologic advances in the field of hemopathology and is subjected to 
periodical review and revisions. [2] 
  
The WHO system groups lymphomas based on their histological patterns, the 
chromosome features of the malignant cells, and the presence of certain 
proteins on the surface of the cells. (Older systems classified lymphomas only 
by how the cells looked under the microscope). The more common types of 
lymphoma are listed below. 
Mature B-cell neoplasms 
 Chronic lymphocytic leukemia/small lymphocytic lymphoma 
 B-cell prolymphocytic leukemia 
 Hairy cell leukemia 
 Splenic marginal zone lymphoma 
o Splenic lymphoma/leukemia, unclassifiable 
o Splenic diffuse red pulp small B-cell lymphoma* 
o Hairy cell leukemia-variant* 
8 
 
 Lymphoplasmacytic lymphoma 
o Waldenström macroglobulinemia 
 Heavy chain diseases 
o Alpha heavy chain disease 
o Gamma heavy chain disease 
o Mu heavy chain disease Plasma cell myeloma 
 Solitary plasmacytoma of bone 
 Extraosseous plasmacytoma 
 Extranodal marginal zone B-cell lymphoma of mucosa-associated 
lymphoid tissue (MALT lymphoma) 
 Nodal marginal zone B-cell lymphoma (MZL) 
o Pediatric type nodal MZL 
 Follicular lymphoma 
o Pediatric type follicular lymphoma 
 Primary cutaneous follicle center lymphoma 
 Mantle cell lymphoma 
 Diffuse large B-cell lymphoma (DLBCL), not otherwise specified 
o T cell/histiocyte rich large B-cell lymphoma 
o DLBCL associated with chronic inflammation 
o Epstein-Barr virus (EBV)+ DLBCL of the elderly 
 Lymphomatoid granulomatosis 
 Primary mediastinal (thymic) large B-cell lymphoma 
 Intravascular large B-cell lymphoma 
 Primary cutaneous DLBCL, leg type 
 ALK+ large B-cell lymphoma 
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 Plasmablastic lymphoma 
 Primary effusion lymphoma 
 Large B-cell lymphoma arising in HHV8-associated multicentric 
Castleman disease 
 Burkitt lymphoma 
 B-cell lymphoma, unclassifiable, with features intermediate between 
diffuse large B-cell lymphoma and Burkitt lymphoma 
 B-cell lymphoma, unclassifiable, with features intermediate between 
diffuse large B-cell lymphoma and classical Hodgkin lymphoma 
 Hodgkin Lymphoma 
 Nodular lymphocyte-predominant Hodgkin lymphoma 
 Classical Hodgkin lymphoma 
o Nodular sclerosis classical Hodgkin lymphoma 
o Lymphocyte-rich classical Hodgkin lymphoma 
o Mixed cellularity classical Hodgkin lymphoma 
o Lymphocyte-depleted classical Hodgkin lymphoma 
Mature T-cell neoplasms 
 T-cell prolymphocytic leukemia 
 T-cell large granular lymphocytic leukemia 
 Chronic lymphoproliferative disorder of NK-cells* 
 Aggressive NK cell leukemia Systemic EBV+ T-cell 
lymphoproliferative disease of childhood (associated with chronic 
active EBV infection) 
 Hydroa vacciniforme-like lymphoma 
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 Adult T-cell leukemia/lymphoma 
 Extranodal NK/T cell lymphoma, nasal type 
 Enteropathy-associated T-cell lymphoma 
 Hepatosplenic T-cell lymphoma 
 Subcutaneous panniculitis-like T-cell lymphoma 
 Mycosis fungoides Sézary syndrome 
 Primary cutaneous CD30+ T-cell lymphoproliferative disorder 
o Lymphomatoid papulosis 
o Primary cutaneous anaplastic large-cell lymphoma 
 Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell 
lymphoma* 
 Primary cutaneous gamma-delta T-cell lymphoma 
 Primary cutaneous small/medium CD4+ T-cell lymphoma* 
 Peripheral T-cell lymphoma, not otherwise specified 
 Angioimmunoblastic T-cell lymphoma 
 Anaplastic large cell lymphoma (ALCL), 
 ALK+ Anaplastic large cell lymphoma (ALCL), ALK–* 
*These represent provisional entities or provisional subtypes of other 
neoplasms. 
Additional information about the 2008 WHO classification. 
Indolent / Aggressive classification 
The following table classifies the lymphoproliferative disorders according to 
whether they belong to the indolent (slow growing) or aggressive subtype. This 
includes lymphomas, leukaemias, and myelomas.  This is based on the 
previous REAL/WHO classification system not the current 2008 WHO system. 
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Indolent lymphoma/leukemia 
 A. Follicular lymphoma (follicular small cleaved cell [grade 1], 
follicular mixed small cleaved and large cell [grade 2], diffuse small 
cleaved cell) 
 B. Chronic lymphocytic leukemia/small lymphocytic lymphoma 
 C. Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia) 
 D. Extranodal marginal zone B-cell lymphoma (MALT lymphoma 
 E. Nodal marginal zone B-cell lymphoma (monocytoid B-cell 
lymphoma) 
 F. Splenic marginal zone lymphoma (splenic lymphoma with villous 
lymphocytes) 
 G. Hairy cell leukemia 
 H. Mycosis fungoides/Sezary syndrome 
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 I. T-cell granular lymphocytic leukemia 
 J. Primary cutaneous anaplastic large cell lymphoma/lymphomatoid 
papulosis (CD30+) 
 K. Nodular lymphocyte predominant Hodgkin's lymphoma   
Aggressive lymphoma/leukemia 
 A. Diffuse large cell lymphoma (includes diffuse mixed cell, diffuse 
large cell, immunoblastic, T-cell rich large B-cell lymphoma) 
Distinguish: 
o 1. Mediastinal large B-cell lymphoma 
o 2. Follicular large cell lymphoma (grade 3) 
o 3. Anaplastic large cell lymphoma (CD30+) 
o 4. Extranodal NK/T-cell lymphoma, nasal type 
o 5. Lymphomatoid granulomatosis (angiocentric pulmonary B-
cell lymphoma) 
o 6. Angioimmunoblastic T-cell lymphoma 
o 7. Peripheral T-cell lymphoma, unspecified 
o 8. Subcutaneous panniculitis-like T-cell lymphoma 
o 9. Hepatosplenic T-cell lymphoma 
o 10. Enteropathy-type T-cell lymphoma 
o 11. Intravascular large B-cell lymphoma 
 B. Burkitt lymphoma/Burkitt cell leukaemia/Burkitt-like lymphoma 
 C. Precursor B- or T-cell lymphoblastic lymphoma/leukaemia 
 D. Primary CNS lymphoma 
 E. Adult T-cell leukaemia/lymphoma (HTLV 1+) 
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 F. Mantle cell lymphoma 
 G. Polymorphic post-transplantation lymphoproliferative disorder 
(PTLD) 
 H. AIDS-related lymphoma 
 I. True histiocytic lymphoma 
 J. Primary effusion lymphoma 
 K. Aggressive NK-cell leukemia/blastic NK-cell lymphoma 
 L. B- or T-cell prolymphocytic leukemia 
 
Staging: 
Once non-Hodgkin lymphoma is diagnosed, tests are done to determine the 
stage (extent of spread) of the disease. The treatment and prognosis (outlook) 
for a patient with non-Hodgkin lymphoma depend in part on the stage of the 
lymphoma. 
Tests used to gather information for staging include: 
 Physical exam 
 Biopsies of enlarged lymph nodes or other abnormal areas 
 Blood tests 
 Imaging tests (CT scans; PET; ultrasonography) 
 Bone marrow aspiration and biopsy (often but not always done) 
 Lumbar puncture (spinal tap – this may not need to be done) 
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Ann Arbor staging system: 
A staging system is a way to summarize the extent of a cancer’s spread. The 
Ann Arbor staging system is most often used to describe the extent of non-
Hodgkin lymphoma in adults. 
The stages are described by Roman numerals I through IV. Lymphomas that 
affect an organ outside the lymph system (an extranodal organ) have E added 
to their stage (for example, stage IIE), while those affecting the spleen have an 
S added. 
Stage I 
Either of the following means the disease is stage I: 
 The lymphoma is in only 1 lymph node area or lymphoid organ such as 
the thymus (I). 
 The cancer is found only in 1 area of a single organ outside of the 
lymph system (IE). 
Stage II 
Either of the following means the disease is stage II: 
 The lymphoma is in 2 or more groups of lymph nodes on the same side 
of (above or below) the diaphragm. For example, this might include nodes 
in the underarm and neck area but not the combination of underarm and 
groin nodes (II). 
 The lymphoma extends from a single group of lymph node(s) into a 
nearby organ (IIE). It may also affect other groups of lymph nodes on the 
same side of the diaphragm. 
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Stage III 
Either of the following means the disease is stage III: 
 The lymphoma is found in lymph node areas on both sides of (above 
and below) the diaphragm. 
 The cancer may also have spread into an area or organ next to the 
lymph nodes (IIIE), into the spleen (IIIS), or both (IIISE). 
Stage IV 
Either of the following means the disease is stage IV: 
 The lymphoma has spread outside the lymph system into an organ that 
is not right next to an involved node. 
 The lymphoma has spread to the bone marrow, liver, brain or spinal 
cord, or the pleura. 
Other modifiers may also be used to describe the lymphoma stage: 
Bulky disease 
This term is used to describe tumors in the chest that are at least one-third as 
wide as the chest, or tumors in other areas that are at least 10 centimeters 
(about 4 inches) across. It is usually designated by adding the letter X to the 
stage. Bulky disease might need more intensive treatment. 
A vs. B 
Each stage may also be assigned an A or B. The letter B is added (stage IIIB, 
for example) if a person has any of the B symptoms listed below: 
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 Loss of more than 10% of body weight over the previous 6 months 
(without dieting) 
 Unexplained fever of at least 38.5°C 
 Drenching night sweats 
These symptoms usually mean the disease is more advanced. If a person has 
any of these, then more intensive treatment is usually recommended. If no B 
symptoms are present, the letter A is added to the stage. 
 
 
 
Indolent Lymphomas: 
'Indolent lymphomas' are a group of malignant lymphomas, so called to 
describe their clinical behavior characterized by a slow growth and spreading 
and few symptoms for long periods. 
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Clinical Presentation 
Although specific subtypes may be associated with specific presenting features, 
there are many common features and the majority of patients present with 
lymphadenopathy. Extranodal disease is common and can affect any organ. 
The most common sites of extranodal disease include the marrow, skin, 
gastrointestinal tract, and bone. Symptoms may be nonspecific or related to the 
site of disease involvement. Many patients with indolent lymphomas are 
asymptomatic, but some, particularly those with bulky disease, may present 
with B symptoms defined as fever, drenching sweats, or weight loss of more 
than 10% of body weight. Patients may present with evidence of bowel 
obstruction from intra abdominal lymphadenopathy and retroperitoneal disease 
may manifest as obstructive uropathy. Inguinal disease may cause compression 
of the venous system with deep venous thrombosis. Central nervous system 
involvement can occur, but is uncommon in indolent lymphomas. [3] 
Diagnosis of Indolent lymphomas 
Suggested guidelines for the diagnosis of indolent lymphomas have been 
outlined by the National Comprehensive Cancer Network and by the European 
Society for Medical Oncology. Diagnosis should be confirmed by excisional 
biopsy of an accessible lymph node with review by a hematopathologist. Fine 
needle aspiration is not indicated, and sufficient material must be obtained for 
immunophenotyping and genetic studies as required for diagnosis and 
prognostic markers. If there are not any easily accessible peripheral nodes, 
computed tomography (CT) or ultrasound guided biopsy are commonly 
tolerated enough. Where possible, consent should be obtained for the 
procurement and storage of use of excess tissue from lymph node biopsies at 
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the time of presentation and at each subsequent relapse of disease for research 
purposes to investigate the molecular biology of these diseases. Marrow biopsy 
provides essential information and should be performed routinely. The yield of 
bilateral marrow biopsy is moderately higher (15%) than that of unilateral 
biopsy. 
Physical examination should include careful examination of all peripheral 
lymph node groups including the cervical, supraclavicular, axillary and 
inguinal chains and examination of Waldeyer ring. Abdominal examination 
should focus on evaluation of any intraabdominal masses, with particular 
attention paid to detection of enlargement of the liver or spleen. The skin 
should be carefully examined. Patients may present with pleural or pericardial 
effusions, although this is less common than in the aggressive lymphomas. 
Laboratory investigations should include a complete blood count to evaluate 
for cytopenias, which may be evidence of marrow infiltration or of 
autoimmunity. A white blood cell count with differential and examination of 
the peripheral blood smear may indicate leukemic involvement. Baseline 
electrolytes including calcium and phosphate, creatinine, and liver function 
tests are important to determine organ dysfunction that may be related to direct 
infiltration by lymphoma. Elevation of lactate dehydrogenase is an important 
prognostic factor and may be a useful indicator of transformation from indolent 
to aggressive lymphoma. Assessment of immunoglobulin levels and serum 
electrophoresis are useful, particularly in lymphoplasmacytic lymphoma, to 
evaluate for monoclonal protein. Cryoglobulins may also be present, 
particularly in marginal zone lymphoma in association with hepatitis C. A 
Coombs test and reticulocyte count may be indicated in patients with anemia. 
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Initial staging workup also includes a CT scan of the chest, abdomen, and 
pelvis, with particular attention to sites of bulk disease and to the number of 
involved sites. Gastrointestinal tract workup and biopsy are indicated in mantle 
cell lymphoma and in patients with mucosa-associated lymphoid tissue 
(MALT) lymphomas. Liver biopsy may be indicated on the basis of abnormal 
imaging or laboratory values. [3] 
 
Indolent Non-Hodgkin's lymphomas (iNHLs) encompass the following low-
grade histologic subtypes B-cell NHL included in the recent World Health 
Organization (WHO) classification of lymphoid neoplasm published in 2008: 
 follicular lymphoma (FL); 
 small lymphocytic lymphoma (SLL); 
 lymphoplasmacytic lymphoma (LPL), which is defined as 
Waldenström's macroglobulinemia (WM) when associated with a 
monoclonal IgM component and bone marrow involvement; 
 splenic marginal-zone lymphoma (SMZL); 
 primary nodal marginal-zone lymphoma (NMZL); 
 marginal-zone lymphoma of mucosa-associated lymphoid tissue 
(MALT). 
FL is the second most common subtype of NHL, accounting for approximately 
25% of newly diagnosed cases of NHL, followed by MALT lymphoma (7% 
including 'gastric' and 'non gastric' cases), while other subtypes are rather rare, 
with SLL, LPL, SMZL and NMZL accounting for 3%, 2%, 2% and 1% of 
NHL patients, respectively. For this reason, given their infrequency with 
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respect for FL, these entities are frequently grouped altogether under the 
category of 'indolent non-follicular lymphoma'  (iNFL). 
 
Type HNL % median survival 
(years) 
Follicular 25% 10 yrs 
Lymphocytic 7% 5-6 yrs 
Lymphoplasmacytic 2% 4-5 yrs 
Mantle 6% 3 yrs 
MALT 7% 6 yrs 
Nodal 2% 4-5 yrs 
Splenic <2% 8-9 yrs 
 
 
Marginal Zone Lymphomas 
The WHO classification lists three forms of marginal zone lymphomas (MZLs) 
including extranodal, nodal, and splenic marginal zone lymphomas. However, 
there are still uncertainties as to whether they represent a homogeneous group 
of tumors. These lymphomas behave differently than most indolent lymphomas 
and require different treatment approaches. [3] 
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The marginal zone (MZ) corresponds to the outer part of secondary follicles. 
It is easily recognizable in the spleen, intraabdominal lymph nodes, and 
MALT. Most MZ cells express CD19 and CD20 and have the phenotypic 
profile of memory B cells and are strongly positive for IgM, IgG, or IgA, only 
a small subpopulation exhibits weak IgD staining. They also express CD21, 
CD27, and Bcl-2 protein, but are negative for CD5, CD10, CD23, CD43, and 
CD75. A subset of splenic MZ cells shares phenotypic features with mantle B 
elements by showing positivity for IgM, IgD, and Ki-B3 and negativity for 
CD21 and CD27. Most, but not all, splenic MZ B cells show somatic 
hypermutation of Ig genes contain point mutations of the Ig genes at 
frequencies found in postfollicular memory B elements. However, a small 
subset of the same MZ B cells displays a low load of Ig gene point mutations, 
as usually found in mantle B cells. Therefore, although belonging to the same 
anatomic compartment, splenic MZ B elements do show a certain phenotypic 
and molecular variability, the vast majority of them being likely part of the 
recirculating memory B-cell pool. Interestingly, splenic MZ B cells can bind 
polysaccharide antigens with one of two results, depending on the follicle 
microenvironment. First, they can migrate into the germinal centers (GCs) and 
present the antigen to GC B cells. If follicular dendritic cells have surface Ig 
that binds to the presented antigen, they proliferate and give rise to the GC cell 
reaction. Second, antigen in association with cytokines released by T cells can 
rapidly induce differentiation of MZ B cells into plasma cells, which in turn 
synthesize and release antigen-specific Ig. MALT lymphomas (extranodal 
marginal zone lymphomas) and monocytoid B-cell NHLs (nodal marginal cell 
lymphomas) are included within the WHO terminology as marginal zone 
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lymphomas. Both types share the presence of positive surface immunoglobulin 
CD19, CD20, and CD22 and are negative for CD5 and CD23. Monocytoid B-
cell lymphoma is the nodal form of marginal zone lymphoma. These patients 
do well, with rates of disease-free and overall survival similar to the other low-
grade lymphomas, as shown in studies conducted by the Southwest Oncology 
Group (SWOG). [3] 
Extranodal Marginal Zone Lymphoma 
In the WHO classification, the term extranodal marginal zone lymphoma is 
restricted to tumors consisting of small elements provided with centrocyte-like 
or monocytoid morphology and associated or not with plasmacytoid 
differentiation, which resemble normal MALT MZ cells and share with them 
phenotypic and molecular characteristics, including the IRTA-1 gene 
expression. In the original description, these neoplasms were called MALT 
lymphomas. 
MALT lymphomas typically arise in the mucosal lymphoid tissue or glandular 
epithelium, including stomach, salivary glands, lungs, or thyroid, with 
gastrointestinal tract involvement being the most common presentation. There 
is a clear association with autoimmune diseases such as Sjogren syndrome and 
Hashimoto thyroiditis. Molecular analysis demonstrates that extranodal MZLs 
are characterized by the occurrence of different chromosomal aberrations, 
t(11;18), t(1;14), and t(14;18), which influence invasive potential and possibly 
the response to therapy. t(11;18)(q21;q21) is detected in 30% to 35% of gastric 
extranodal MALT lymphomas producing the fusion gene API2-MALT1, 
leading to the overexpression of the API2 gene, which inhibits apoptosis via 
the caspase system. Presence of the t(11;18) is associated with antibiotic 
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resistance, a higher potential of local infiltration and metastasis and 
progression to a more aggressive tumor. This translocation is found even more 
frequently in the lung than in the stomach and is found also in approximately 
one-half of the rare examples of gastric Helicobacter pylori (HP)-negative 
MZL, further supporting the concept that tumors carrying t(11;18) do not need 
HP stimulation for their growth and maintenance. The t(1;14)(p22;q32) is 
exceedingly rare and causes transfer of the BCL10 gene close to the Ig 
enhancer on chromosome 14. The role of the t(14;18)(q32;q21) in MZL has 
been the subject of much debate in the literature, with confusion with the 
translocation found in FL. Although the t(14;18) of MZLs does not affect 
BCL2, it affects MALT1 by possibly following the same pathogenetic pathway 
as the t(1;14). Bacterial infection with the gramnegative rod H pylori is 
associated with 92% of gastric MALT lymphomas. 
Large B-cell lymphoma can arise at an anatomic site containing MALT, which 
has been named “high-grade MZ/MALT lymphoma,” a term not included in 
the WHO classification. There is no evidence that large B-cell lymphoma 
occurring de novo at a MALT site is derived from MZ cells; and the clonal 
relationship between an MZL and a large B-cell neoplasm simultaneously 
detected in the same organ should be proven molecularly, as the latter can 
represent the blastic phase of the former, but might also develop as a second 
unrelated neoplasm. [3] 
Nodal Marginal Zone Lymphoma 
In the WHO classification, nodal marginal zone lymphoma (NMZL) is defined 
as a primary nodal B-cell neoplasm that morphologically resembles lymph 
nodes involved by MZ lymphoma of the extranodal  or splenic type, but 
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without evidence of extranodal or splenic disease. This suggests that the terms 
extranodal, nodal, and splenic MZL refer to different clinical presentations of 
the same disease. 
Nodal marginal zone lymphoma is clinically more aggressive than the 
extranodal and splenic forms and has a higher incidence of advanced-stage 
disease and lower 5-year overall and disease-free survival. In addition, 10% to 
20% of cases transform into a DLBCL. Most cases display a distinct 
“monocytoid” appearance, and the tumor was originally termed monocytoid B-
cell lymphoma. Molecular studies strengthen the concept of significant 
differences among the three types of MZL. The t(11;18) does not occur in 
nodal MZL. Analysis of IgVH gene demonstrates that some nodal MZLs carry 
somatic mutations whereas others do not, suggesting derivation from post-GC 
and virgin B cells, respectively. Among mutated cases, usage of specific IgVH 
gene segments seems to occur frequently and to discriminate between HCV-
positive and -negative patients. None of the translocations characteristically 
recorded in splenic MZL, including del(7q), del(13q14), and del(10)(q22,q24), 
has been detected in nodal MZL. [3] 
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Splenic Marginal Zone Lymphoma 
Splenic marginal zone lymphoma is generally characterized by splenomegaly 
and leukemic spread, even if at times cases with disseminated disease or 
exclusively leukemic presentation have been reported. In approximately half of 
the cases, circulating neoplastic cells display cytoplasmic villous projections, 
which justify the term splenic lymphoma with villous lymphocytes. Infiltration 
of the marrow occurs in most if not all patient S. Molecular studies shows that 
splenic MZL is a heterogeneous tumor with chromosomal abnormalities 
including del(7q), del(13q14), and del(10)(q22,q24).  Splenic Marginal Zone 
Lymphoma (SMZL) is a rare B-cell indolent lymphopoliferative disorder (less 
than 2% of all Non Hodgkin's lymphomas - NHL) that characteristically affects 
elderly or middle age patients, with median survival longer than 10 years [1-4]. 
Malignant cells present features of mature activated B-lymphocytes, with 
expression of CD19, CD20, CD22, CD79b, FMC7, and with light chain 
restriction. In the majority of cases, neoplastic lymphocytes are negative for 
CD5, CD23, CD10, and CD103. Bone marrow infiltration pattern is typically 
intrasinusoidal, but it can become nodular during disease progression or after 
splenectomy [5,6]. 
SMZL characteristically presents massive splenomegaly, abdominal 
discomfort, lymphocytosis and cytopenias, often related to hypersplenism. 
Lymphonodes and/or organ involvement are infrequent  at the diagnosis, but 
they may develop with progression of disease. B symptoms are present in 25%  
up to 60% of cases, and autoimmune phenomena are not uncommon (15-20% 
of patients). Serum paraproteinemia, usually less than 20 g/L, is observed in 
about 10-25% of patients. Association with  HCV infection has been registered 
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more frequently in South Europe countries, supporting a role of HCV in 
lymphoma genesis. No specific prognostic factors have been still established 
for SMZL: high tumour mass, hemoglobin level less than 12 g/dl, increased 
LDH, albumin less than 3.5 g/dL, and increased beta2 microglobulin at 
diagnosis have been described as adverse prognostic factors [1,4,7,8]. 
In particular, the Intergruppo Italiano Linfomi (ILL) defined a prognostic score 
system based on LDH, albumin and haemoglobin levels identifying 3 different 
risk groups: low, intermediate and high [8]. 
 
The overall prognosis of SMZL is quite good in most patients. The percentage 
of patients surviving 5 years from diagnosis is 65 to 75%, often even in the 
absence of treatment or of a complete response to therapy. There is no clear 
advantage in a precocious treatment, that is considered indicated only when 
patients develop significant signs and/or symptoms (severe cytopenias, 
symptomatic splenomegaly, recurrent infections, systemic symptoms). A 
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“watch and wait” policy is also reasonable for asymptomatic patients who have 
moderate cytopenias and no-bulky splenomegaly. 
Two-thirds of patients do not have symptoms at diagnosis, and up to one-third 
of those may never require anti-lymphoma treatment [1,4]. 
Patients presenting with symptomatic (usually painful) splenomegaly are most 
often treated by splenectomy. This approach often results in a remission lasting 
several years. If patients have splenomegaly and are HCV-positive, treatment 
with the anti-hepatitis drugs, such as alpha-interferon and ribavirin may be 
considered and offers good rate of responses [9,10]. 
Patients with advanced disease are candidates for more aggressive therapy; 
purine analogs, such as fludarabine and cladribine, seem to produce higher 
response rates, although no standard regimen exists [11,12,13]. The therapeutic 
impact of Cladribrine (2-chlorodeoxyadenosine-2-CdA) is not yet defined, with 
different response rates, up to 80% [14,15,16]. 
Moreover, Rituximab showed significant activity in SMZL.  Treatment with 
rituximab in symptomatic patients seems to be superior to splenectomy and 
often leads to normalizing of blood counts and disappearance of splenomegaly. 
Rituximab is synergistic with chemotherapy and it is often added to whichever 
regimen is chosen [17,18,19,20].  
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Treatment of indolent lymphomas 
For most cases of indolent lymphoma, the goal of therapy has been to maintain 
the best quality of life and to treat only when patients develop symptoms. Any 
alteration to this approach requires demonstration of improved survival with 
early institution of therapy, or identification of criteria that define patients 
sufficiently high-risk to merit early therapy. There are many available therapies 
and no consensus on an optimal first-line or relapse treatment. Despite a 
paucity of data demonstrating any benefit for early therapy, patients are being 
treated earlier in their disease course. There is no clear cut treatment pathway 
for patients with indolent lymphomas and little or no data regarding the optimal 
sequencing of treatment approaches in these diseases. In the absence of such 
data, treatment choices remain empiric and should always involve discussion 
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regarding patient choice and goal of therapy. Decisions concerning therapy are 
likely to become even more complicated because many novel agents are 
currently being investigated in preclinical and clinical studies, particularly, 
novel monoclonal antibodies and agents that alter the antiapoptotic pathways. 
Enrollment of patients on properly conducted clinical trials should be 
encouraged until we have a clear-cut established treatment approach that leads 
to cure for the majority of patients. 
Options for treatment of low-grade lymphomas include a watch and wait 
approach, single-agent chemotherapy, or monoclonal antibody therapy with 
rituximab, combination chemoimmunotherapy, and the use of autologous or 
allogeneic hematopoietic cell transplantation (HCT). Patients remaining on an 
expectant course should be followed every 3 months with history, physical 
examination, and blood counts, including lactate dehydrogenase. Special 
attention should be paid to any change in symptoms that might be suggestive of 
transformation, which should be an indication for repeat biopsy to examine for 
histologic evidence to confirm transformation. The role of routine repeat 
scanning remains unclear. 
Because there is no clearly defined treatment algorithm for most patients with 
indolent lymphomas, eligible patients should be included whenever possible in 
clinical trials. This ensures delivery of optimal care and helps inform design of 
subsequent trials, hopefully leading to cure.  [3] 
When to institute therapy 
With the exception of patients enrolled in clinical trials assessing the impact of 
early therapy, expectant management is the treatment of choice for 
asymptomatic patients with low bulk disease until clear indications for 
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initiation of treatment are seen. This approach is based on the demonstration of 
no survival advantage for institution of immediate compared with deferred 
treatment until time of progression.  Three randomized trials, performed in the 
pre-rituximab era, confirmed no survival benefit for early therapy. In the 
National Cancer Institute study in 104 newly diagnosed patients with FL, 
deferred treatment was compared with immediate treatment with ProMACE-
MOPP followed by total nodal irradiation. An updated analysis of the data is 
long overdue, but there was no difference in overall survival (OS) between the 
two arms at the time of the last analysis. The Groupe pour l’Etude de 
Lymphome Folliculaire (GELF) used defined criteria for patients in whom 
immediate therapy was not felt to be indicated and randomized 193 patients to 
deferred treatment or to receive prednimustine 200 mg/ m2/day for 5 days per 
month for 18 months or interferon-alpha (IFN-alfa) 5 MU/day for 3 months, 
then 5 MU three times per week for 15 months. The median OS time was not 
reached and was the same in all three arms of the study. The British National 
Lymphoma Investigation compared treatment in 309 patients with 
asymptomatic advanced-stage, indolent lymphoma in whom 158 patients were 
randomized to receive immediate therapy with oral chlorambucil 10 mg per 
day continuously and 151 patients randomized to deferred treatment until 
disease progression. In both arms, local radiotherapy to symptomatic nodes 
was allowed. There was no difference in OS or cause-specific survival between 
the two groups with 16 years’ median follow-up. A meta-analysis of more than 
2000 patients with early-stage CLL/SLL showed no difference in survival 
between early versus deferred therapy using alkylating agents. 
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A major clinical trial question is whether identification of clinical or molecular 
risk factors can identify which patients are candidates for early therapy. A 
survival predictor score has also been developed from gene expression 
profiling studies. The results from this study suggest that the molecular 
determinants of biological heterogeneity are already present in the diagnostic 
lymph node biopsies rather than by the later acquisition of secondary genetic 
changes. A major component of the gene expression prognostic signature is 
related to immune cells in the tumor microenvironment. Future guidelines for 
treatment will likely be based on clinical staging systems, genetic profiles, and 
immune response signatures, but these factors do not yet help us to decide who 
should receive immediate therapy. [3] 
From available data, there is little to suggest that we should change our practice 
of “watch and wait” for asymptomatic low bulk patient, but data demonstrate 
that this practice is becoming much less common in the USA. The National 
Lymphocare Study is a prospective observational study designed to assess 
presentation, prognosis, treatment, and clinical outcomes in newly diagnosed 
FL. The treating physician determines management according to clinical 
judgment with no prescribed treatment regimen and data regarding histology, 
stage, therapy, response, relapse, and death are recorded. Among 1493 patients 
enrolled at 237 centers, 26% of initially observed patients had switched to 
active therapy after a median of 2.8 months on observation since diagnosis, and 
by the first follow-up visit only 19% of patients continued on watch and wait at 
6 months. This observation is in stark contrast to the data from the British 
National Lymphoma Investigation (BLNI) study demonstrating that (censored 
for nonlymphoma death) 19% of patients and 40% for those older than 70 
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years who were randomized to expectant management still did not require 
therapy at 10 years. [3] 
Treatment approaches 
Treatment is indicated in patients with symptomatic disease, bulky 
lymphadenopathy, and/or splenomegaly; risk of local compressive disease; 
marrow compromise; or rapid disease progression. Once indicated, numerous 
treatment approaches are available. The concept that the approach can be to 
“do nothing” or discuss an approach with considerable morbidity and mortality 
such as hematopoietic cell transplantation is a confusing one for the newly 
diagnosed patient (as well as for the physician), and considerable consultation 
time is required to review available treatment approaches. Staging of response 
in indolent lymphomas is by the revised response criteria. Depending on the 
treatment approach used, restaging after two to three cycles of therapy can be 
useful to ensure responsiveness with full restaging after completion of therapy. 
Whereas curative approaches are being sought in indolent lymphomas, the 
failure to achieve complete remission (CR) does not have the same implication 
in indolent lymphomas as in aggressive lymphomas, and a PR may be a 
sufficient response to therapy to alleviate symptoms. 
Optimal first-line treatment is enrollment in randomized clinical trials. In the 
National Lymphocare Study, academic sites are more likely than community 
sites to treat patients on clinical trials (12% vs 4%), but it is lamentable that 
such a small proportion of these patients are enrolled in clinical trials. For 
patients who are not eligible for or who refuse entry into clinical trials, there 
are data demonstrating higher response rates and longer duration of responses, 
and perhaps improved survival with chemoimmunotherapy. Many investigators 
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favor alkylator- over fludarabine-based regimens for FL, based on concerns 
regarding the ability to obtain stem cells for later use for autologous HCT in 
fludarabine-treated patients. It is suggested that more aggressive first-line 
therapy should be offered to patients who progress within 1 year of 
presentation, because these patients have a worse outcome. Elderly patients or 
those with poor performance status remain candidates for single-agent 
chlorambucil. Single-agent monoclonal antibody therapy is appropriate for 
patients who chose to avoid chemotherapy and is a reasonable treatment choice 
based on the results of clinical trials of prolonged or maintenance therapy with 
rituximab. Although data suggest a survival advantage with the use of IFN-alfa 
in combination with chemotherapy, this is associated with a significant side 
effect profile and this agent is rarely used in the USA. Optimal results are seen 
when radioimmunoconjugates are used earlier in the disease course. There is 
no indication for the use of high-dose therapy and HCT in first remission in FL 
except in the context of a properly conducted clinical trial. 
Data from the National Lymphocare study demonstrate that 
chemoimmunotherapy is now the treatment of choice of physicians in the USA. 
No randomized trials demonstrate a benefit for the addition of anthracyclines, 
but cyclophosphamide, adriamycin, vincristine, prednisone, and rituximab 
(CHOP-R) is heavily favored over cyclophosphamide, vincristine prednisone, 
and rituximab (CVP-R) or fludarabine-based regimens. Choice to initiate 
therapy was associated with FLIPI, stage, and grade but FLIPI was not 
associated with the decision to utilize a specific treatment approach. Significant 
regional and center differences were observed, strongly suggesting that 
physician preference is the predominant factor that drives initial therapy. For 
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example, initial “watch and wait” was used in 31% in the Northeast, but in 
13% in the Southeast, whereas fludarabine-based chemoimmunotherapy was 
used in 18% of patients in the Southwest and only 3% in the Northeast. [3] 
Alkylating Agents 
The alkylating agents chlorambucil and cyclophosphamide with or without 
prednisone and CVP or CHOP, and other alkylator-based combination 
chemotherapy regimens, have been the standard of therapy for decades. Single-
agent alkylators at different doses and schedules produce overall response (OR) 
rates of 50% to 75% in FL. Comparable response rates but higher complete 
remission rates with longer progression-free survival (PFS) are seen with CVP 
compared to chlorambucil, but there is no survival advantage. The addition of 
anthracyclines has not improved the response rate or duration of the response, 
but its use may be associated with a lower risk of histologic transformation. 
This finding has to be confirmed, particularly in the era of 
chemoimmunotherapy. 
Purine Analogues 
The purine analogues have been studied extensively in various types of 
indolent lymphoma. Fludarabine monotherapy produces response rates of 65% 
to 84%, with 37% to 47% CR in previously untreated FL patients. In a 
randomized trial of 381 previously untreated indolent lymphoma patients, CR 
rates were higher with fludarabine than CVP. Fludarabine combinations result 
in increased response rates, with 89% CR rate in an Eastern Cooperative 
Oncology Group trial combining fludarabine and cyclophosphamide, whereas 
fludarabine and mitoxantrone produced a 91% overall response rate, 43% CR, 
and 63% 2-year disease-free survival. A higher CR rate was seen with 
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fludarabine and mitoxantrone (68%) compared to CHOP (42%) in a 
randomized trial. The use of alkylator-based regimens or purine analog-based 
regimens appears to vary geographically, suggesting personal preference for 
the use of regimens in which the clinician has experience, rather than 
alterations of practice based on the results of the published studies. In 
CLL/SLL, fludarabine is associated with a higher response rate and longer 
duration of response than chlorambucil, but no OS advantage. The use of 
fludarabine in combination with cyclophosphamide is associated with a higher 
response rate and longer duration of response compared with fludarabine alone 
in randomized trials. The highest response rates have been with fludarabine, 
cyclophosphamide, and rituximab. [3] 
Biologic Therapy 
IFN-alfa is approved by the Food and Drug Administration (FDA) for the 
treatment of advanced-stage FL in combination with anthracycline- based 
chemotherapy, based on improved survival in a clinical trials and meta-analysis 
of phase III trial data. IFN-alfa has been widely used in Europe but not in the 
USA, where it is felt that its toxicity profile outweighs any potential benefit. In 
the SWOG study, 571 patients with stage III and IV indolent lymphoma were 
treated with ProMACE-MOPP, and 279 responding patients were randomized 
to 24 months of observation versus treatment with IFN-alfa. No statistically 
significant difference in PFS or OS was observed between observation and 
IFN-alfa groups at 4 years. [3] 
Monoclonal Antibody Therapy 
Monoclonal antibodies are the most exciting agents to emerge in the treatment 
of indolent lymphomas, and recent data suggest their use may finally be 
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leading to improvement in patient survival. The most widely used monoclonal 
antibody is rituximab, a chimeric unconjugated antibody against the CD20 
antigen licensed by the FDA and the European Agency for the Evaluation of 
Medicinal Products for treatment of patients with relapsed or refractory, CD20-
positive low-grade FL; for the first-line treatment of CD20- positive FL in 
combination with CVP chemotherapy; and for the treatment of CD20-positive 
low-grade NHL in patients with stable disease or who achieve a PR or CR 
following first-line treatment with CVP chemotherapy. 
Following phase I studies, rituximab at a dose of 375 mg/m2 weekly for 4 
weeks was selected for the pivotal phase II trial and this remains the standard 
dose. In relapsed indolent lymphoma patients, OR was 48% and 60% in FL. 
Median PFS for responders was 13 months. Factors associated with lower 
response rates include chemoresistant disease, bulky disease, and treatment late 
in the disease course. The incidence of OR was 73% in previously untreated 
patients with low bulk disease, and some of these patients have needed no 
further treatment and have no evidence of polymerase chain reaction-detectable 
minimal residual disease after 7 years. Extended use with 8 weeks instead of 
four is associated with improvement in OR and duration of response. 
Comparable or even longer durations of response have been observed with 
retreatment. 
A number of trials in front-line and in relapsed/refractory patients have 
investigated the potential benefits of extended or maintenance rituximab 
treatment and all demonstrated prolonged time to progression in patients 
receiving maintenance rituximab. The results from the E1496 randomized trial 
from the Eastern Cooperative Oncology Group and the Cancer and Leukemia 
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Group B comparing CVP alone to CVP followed by rituximab in patients with 
advanced-stage FL demonstrated that addition of rituximab maintenance 
significantly improved OS and led to FDA approval for rituximab therapy in 
patients responding to CVP chemotherapy. A problem with interpretation of 
the role of maintenance therapy or in recommending a specific regimen is that 
there is no standard schedule and trials have been performed in rituximab-naïve 
patients as well as in patients treated with previous rituximab monotherapy or 
combination chemoimmunotherapy. 
Chemoimmunotherapy 
In a phase II study, 40 patients with indolent lymphoma were treated with six 
infusions of rituximab (375 mg/m2 per dose) in combination with six doses of 
CHOP chemotherapy (R-CHOP). Overall response was 95%, with a CR of 
55% and OR of 45% in patients with bulky disease. In a phase II study of 40 
patients with indolent lymphomas, rituximab in combination with fludarabine 
produced OR of 90% and CR of 80%, with similar response rates in 
treatmentnaïve and previously treated patients. 
A number of randomized trials show a benefit for the use of rituximab with 
chemotherapy compared to chemotherapy alone. Each study showed an 
improvement in time to treatment failure. More recent follow-up data suggest 
improved OS in patients treated with chemoimmunotherapy compared to 
chemotherapy alone. A meta-analysis of these trials demonstrates that OS, OR, 
and disease control are significantly better in those on chemoimmunotherapy 
compared to chemotherapy for FL and mantle cell lymphoma. Data from the 
German Low-Grade Study Group suggest that it is the addition of rituximab 
that has led to the recent improvement in survival of patients with FL. A recent 
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independently assessed analysis of the clinical benefits provided by rituximab 
in relation to cost concluded that it is highly cost-effective. 
Conjugated Radiolabeled Monoclonal Antibody Therapy 
Binding a radioisotope to a monoclonal antibody (radioimmunoconjugate) 
might be expected to improve efficacy over antibody therapy alone. 
Tositumomab joins 131I to the anti-B1 antibody and has been studied 
extensively in the treatment of heavily pretreated and untreated lymphomas and 
for retreatment of indolent lymphomas. Best responses are seen in previously 
untreated FL patients with a 95% OR and 75% CR. Eighty percent of 
assessable patients achieved eradication of polymerase chain reaction-
detectable minimal residual disease after a single treatment course with 
tositumomab. Median PFS was 6.1 years, with 40 patients remaining in 
remission for 4.3 to 7.7 years and no cases of myelodysplastic syndrome 
observed. A SWOG study investigated chemoimmunotherapy with six cycles 
of CHOP chemotherapy followed 4 to 8 weeks later by tositumomab in 90 
patients with previously untreated, advancedstage FL. The OR was 91%, 
including 69% CR and at median follow-up time of 5.1 years, the estimated 5-
year OS was 87% and PFS 67%. These results were significantly better than 
results of therapy with CHOP alone on previous SWOG protocols. 
Ibritumomab Tiuxetan is a 90Y-labeled anti-CD20 antibody and produced an 
OR of 74% and CR of 15% in 57 FL patients refractory to rituximab. Toxicity 
is primarily hematologic, with nadir counts occurring at 7 to 9 weeks and 
lasting approximately 1 to 4 weeks. The risk of hematologic toxicity increased 
with dose delivered and with degree of baseline marrow involvement.  An 
acceptable safety profile was observed in relapsed patients with less than 25% 
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lymphoma marrow involvement, adequate marrow reserve, platelets greater 
than 100,000 cells/microL, and neutrophils greater than 1500 cells/microL. 
High-Dose Therapy as Consolidation of First Remission 
The role of high-dose therapy and autologous HCT in FL patients during first 
remission was explored in phase II trials, and in three phase III randomized 
trials. The German Low-Grade Study Group trial recruited 307 previously 
untreated patients up to 60 years of age. Patients who responded after induction 
chemotherapy with 2 cycles of CHOP or mitoxantrone–chlorambucil–
prednisone were randomized to autologous HCT or IFN-alfa maintenance. 
Among 240 evaluable patients, the 5-year PFS was 64.7% for autologous HCT 
and 33.3% in the IFN-alfa arm (P = .0001). Acute toxicity was higher in the 
autologous HCT group, but early mortality was below 2.5% in both study 
arms. Longer follow-up is necessary to determine the effect of autologous HCT 
on OS. In the Groupe Ouest Est des Leucemies Aigues et des Maladies du 
Sang study, 172 newly diagnosed advanced FL patients were randomized 
either to cyclophosphamide, doxorubicin, teniposide, prednisone (CHVP) and 
IFN-alfa or to high-dose therapy followed by purged autologous HCT.105 
Patients treated with high-dose therapy had a higher response rate than patients 
who received chemotherapy and IFN-alfa (81% vs 69%, P = .045) and a longer 
median PFS (not reached versus 45 months), but this did not translate into a 
better OS because of an excess of secondary malignancies after transplantation. 
A subgroup of patients with a significantly higher event-free survival rate 
could be identified using the FLIPI. The GELF-94 study enrolled 401 
previously untreated advanced-stage FL patients who were randomized to 
receive CHVP plus IFN-alfa compared with four courses of CHOP followed by 
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HDT with total body irradiation and autologous HCT. Overall response rates 
were similar in both groups (79% and 78%, respectively), and 87% of eligible 
patients underwent autologous HCT. Intent-to-treat analysis after a median 
follow-up of 7.5 years showed no difference between the two arms for OS 
(P=.53) or PFS (P =.11). Long-term follow-up demonstrated no statistically 
significant benefit in favor of first-line autologous HCT in patients with FL. In 
view of these results, autologous HCT should be used in first remission only in 
the setting of clinical trials. 
Treatment of relapsed indolent lymphoma 
The treatment options after relapse remain the same as for first-line therapy, 
and relapsed patients should ideally be treated in clinical trials. Relapsed 
asymptomatic disease is not necessarily an indication for treatment and patients 
can again be managed expectantly. A number of factors must be taken into 
account in planning therapy and it is not possible to define treatment at relapse 
without considering the goal of therapy (palliative vs potentially curative) 
performance status, previous therapy, response, and duration of response. 
Single agent rituximab is approved for relapsed lymphoma and is widely used 
in this setting. A multicenter randomized trial in relapsed patients has 
demonstrated a survival advantage for chemoimmunotherapy with CHOP-R or 
CHOP followed by R compared to CHOP alone, and a further benefit for 
rituximab maintenance therapy. For younger patients who are suitable 
candidates for autologous HCT or reduced-intensity conditioning (RIC) 
allogeneic transplantation, referral to a transplant center should be considered 
early to discuss the potential role and timing of transplantation. Best results are 
seen when transplantation is considered early in the course of disease before 
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patients become chemorefractive. Hematopoietic cell transplant approaches 
must be considered in the context of the improving results that are being seen 
with salvage therapy alone. The results of autologous HCT have been 
disappointing for CLL/SLL; however, RIC allogeneic transplants appear 
promising in selected patients with this disease. 
The Role of Transplant in Relapsed Indolent Lymphomas 
Unlike aggressive lymphomas, the use of high-dose chemotherapy with 
autologous HCT in the treatment of indolent lymphomas has not yet been fully 
established. The rationale for considering transplantation is that the disease is 
incurable using standard approaches, and promising results have been observed 
in a number of phase II studies. Detection of minimal residual disease has been 
a useful surrogate marker for tracking long-term PFS in patients examining the 
autologous stem cells or serial samples after transplantation. A major concern 
relates to the risk of secondary myelodysplasia/acute myeloid leukemia. The 
European Bone Marrow Transplant Registry- sponsored CUP study 
(conventional chemotherapy, unpurged, purged autograft) is the only 
prospective randomized trial to assess the role of autologous HCT in patients 
with relapsed FL. The results of the study suggest a PFS and OS advantage of 
autologous HCT over conventional chemotherapy, with a 4-year OS of 46% for 
the chemotherapy arm, versus 71% for the unpurged and 77% for the purged 
autologous HCT arms. The study was closed early because of slow accrual 
with 140 of the planned 250 patients accrued and only 89 randomized. In 
CLL/SLL, the use of autologous HCT was not associated with improved 
outcome in patients transplanted in first remission compared to those 
transplanted later in their disease course. 
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Allogeneic Hematopoietic Cell Transplant 
There is a trend toward increasing use of allogeneic HCT in the management of 
indolent lymphomas. In a report of the International Bone Marrow Transplant 
Registry, results after HCT are described for 904 patients with FL. Among 
these patients, 176 patients underwent allogeneic HCT, and 131 patients 
underwent autologous HCT using a purged inoculum and 597 using an 
unpurged autologous inoculum. The treatment-related mortality (TRM) in 
these three groups was 30%, 14%, and 8%, respectively, disease recurrence in 
21%, 43%, and 58% and 5-year OS was 51%, 62%, and 55%, respectively. The 
use of total body irradiation-containing regimens was associated with increased 
TRM but decreased risk of relapse. The use of allogeneic HCT was associated 
with increased TRM but significantly lower risk of disease recurrence in 
keeping with a graftversus- lymphoma effect in this disease. It should be noted 
that the majority of allogeneic transplant recipients reported in these studies 
received a fully myeloablative regimen. Long-term PFS has been observed 
after allogeneic SCT even in patients with refractory FL. In 29 FL patients, 11 
of whom had refractory disease, the nonrelapse mortality was 24% and there 
was a 23% incidence of relapse. The 5-year OS was 58%, with 53% event-free 
survival. Patients who have relapsed after previous autologous HCT have a 
very poor prognosis. The outcome following myeloablative allogeneic HCT of 
114 such patients has been reported from the International Bone Marrow 
Transplant Registry. The TRM was 22% and the probability of disease 
progression was 52% at 3 years. The use of total body irradiation conditioning 
regimens and achievement of CR at the time of allogeneic HCT were 
associated with improved outcome. The use of RIC regimens appears to be 
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associated with improved outcome. In 20 such patients, there was only one 
TRM from fungal infection and the 3-year progression-free survival was an 
excellent 95%. The out-come following RIC transplant regimen incorporating 
alemtuzumab immunosuppressive therapy has been reported for 81 patients 
with lymphoma, including 41 with low grade, 37 with high/intermediate grade, 
and 10 patients with MCL, 31 of whom had relapsed following previous 
autologous HCT. Patients received a conditioning regimen consisting of 
alemtuzumab, fludarabine, and melphalan, and received short-course 
cyclosporine as GVHD prophylaxis. The use of this conditioning regimen was 
associated with a low incidence of GVHD and TRM was decreased in patients 
with low-grade compared to higher-grade histology. The 3-year progression-
free survival was 65% for patients with low-grade lymphoma, 50% for patients 
with MCL, and 34% for high-grade lymphoma (P = .002). Donor lymphocyte 
infusion was given to 36 patients, 21 for relapsed or persistent disease and 15 
for persistence of mixed chimerism. Investigators hypothesize that the use of 
donor lymphocyte infusion to treat relapse after allogeneic HCT will stimulate 
an effective graftversus- lymphoma response. In one series, seven patients with 
FL and SLL who had relapsed after prior allogeneic HCT received donor 
lymphocyte infusion. Six patients responded and four experienced CRs, which 
have been maintained for 43 to 89 months. The effectiveness of donor 
lymphocyte infusion to treat relapse after allogeneic HCT provides very strong 
evidence for a graft-versuslymphoma effect that can be exploited in indolent 
lymphomas. [3] 
 
 
44 
 
Special consideration for treatment of SMZL 
There are still contrasting opinion about the optimal therapeutic approach in 
this disease. Most studies have suggested better outcomes for those patients 
who underwent splenectomy, suggesting that splenectomy may be the first-line 
treatment choice, but this can be delayed until the occurrence of symptoms or 
cytopenia and seems to be sufficient for correcting cytopenic manifestations, 
improving quality of life and increasing survival (with median values of 
between 9 and 13 years). The utility of alternative approaches, including 
chemotherapy, radiotherapy, or immunotherapy, is the subject of prospective 
clinical trials. Adverse prognostic predictors include hemolytic anemia, 
immune thrombocytopenia, M-component in the serum, elevated beta2-
microglobulin level, leukocyte count >20,000/microL, lymphocytes 
>9000/microL, and p53 overexpression by neoplastic cells. Progression to 
DLBCL has been recorded rarely. [3] 
Novel agents of indolent lymphoma 
Overall, iNHLs are highly responsive to standard chemotherapy regimens, but 
still remain incurable, showing a relentless progressive-relapsing course. In the 
pre-rituximab era median survival for advanced iNHL was around 8-10 years 
and after relapse it became around 4-5 years. In the last decade, however, the 
advent of rituximab-based immunochemotherapy not only increased overall 
response rate (ORR) and complete response (CR) rate, but prolonged 
progression-free survival (PFS) and overall survival (OS). Furthermore, the 
introduction of the radio-immuno-conjugates 90-yttrium labelled ibritumomab 
tiuxetan and 131-iodine labelled tositumomab has shown promising results in 
terms of efficacy and safety in either front-line, consolidation or 
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relapsed/refractory settings, including in some cases long-term remissions. In 
addition, the increasing understanding of molecular mechanisms involved in 
the pathogenesis of iNHL has opened the door to the discovery and 
development of several new targeted therapies that in the near future could 
challenge the current scenario. [4] 
Chemotherapeutic agents 
BENDAMUSTINE: bendamustine is an 'old' alkylating agent that has been 
'rediscovered' recently and has undergone extensive clinical development. It 
was first synthesized in 1963 by Ozegowski and it has been used in Germany 
since 1971 for the treatment of several haematologic malignancies. The 
chemical structure of bendamustine consists of a nitrogen mustard linked to a 
benzimidazole ring, which is thought to confer purine-analogue properties, and 
a butyric acid side chain. Experimental evidence of its unique mechanism of 
action has demonstrated: (1) a potent ability to induce sustained double strand 
breaks; (2) the induction of unique DNA repair; (3) the induction of apoptosis 
via extrinsic and intrinsic pathways (p53, NOXA, caspases cascade); (4) the 
deregulation of the cell cycle through the inhibition of mitotic checkpoints; and 
(5) the induction of apoptosis-independent forms of cell death ('mitotic 
catastrophe'). As a result, bendamustine displays significant mechanistic 
differences from other alkylating agents, exhibiting greater stability and slower 
repair of DNA damage. In preclinical models bendamustine demonstrated 
significant synergism with rituximab. 
 
Beginning in the late 90s, many German groups have performed an increasing 
number of pilot trials evaluating bentamustine in NHL. These studies showed a 
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remarkable activity and a very favourable side-effects profile, characterized 
primarily by moderate haematological toxicity, mild nausea and a quite 
inconsistent rate of alopecia. Two large US phase II multicentre studies 
investigated bendamustine monotherapy in patients with rituximab refractory 
in iNHL. In the first, bendamustine showed a favourable side-effect profile 
with good clinical activity: grade 3-4 toxicities were prevalently hematological, 
including reversible neutropenia (54%) and thrombocytopenia (25%); the ORR 
was 77% (CR/CRu 34%), with a median duration of response (DOR) of 9 
months.The second study showed similar results (ORR 75%, CR/CRu 17%; 
median PFS 9.3 months). Of note, the efficacy of bendamustine was 
comparable between the different indolent histological sbtypes: the ORR was 
74% in FL, 71% in SLL, 86% in MALT-MZL and 78% in NMZL patients. 
Taken together, these studies demonstrated a promising clinical activity and a 
good safety profile for bendamustine in patients with rituximab-refractory 
iNHL. However, the duration of remission was rather short. [4] 
 
To improve these results, the logical next step was to combine bendamustine 
with rituximab (BR). Two similar trials investigated this combination in 
relapse/refractory iNHL. In the first study, Rummel and collegues treated 63 
patients with FL, iNFL or MCL with the BR regimen. Leukopenia was the 
most common side-effect (16% grade 3-4); no evidence of cumulative 
myelosuppression was found. None of the patients suffered from alopecia and 
no organ toxicity was seen. The response rate was promising (ORR 90%, CR 
60%) and, importantly, responses were fairly durable, with median PFS of 24 
months. Notably, PFS in FL and PLP patients was even higher (median not 
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reached). The second trial showed almost identical results, in term of toxicity 
profile (36% grade 3-4 neutropenia) and efficacy (median PFS of 23 months).  
 
As a consequence of these results in the relapsed/refractory setting, the StiL 
group performed a phase III randomized study comparing six cycles of BR 
with six cycles of R-CHOP as first-line therapy in 514 patients with FL, iNFL 
and MCL. The final results of this study were reported at the ASH meeting in 
2000 and updated at the last ASCO meeting. BR was more effective than R-
CHOP with a median PFS of 69.5 months versus 31.2 months. The advantage 
in term of PFS was evident in all risk groups and histologic subtypes, with the 
exception of the small subgroup of MZL. OS was not significantly different 
between the two treatment regimens. Concerning adverse events, R-Chop was 
more toxic than BR (grade 3-4 neutropenia 46.5% versus 10.7%). In addition, a 
sub-analysis of this study showed that the BR combination did not impair the 
collection of stem cells for subsequent transplant, since the mobilization 
performed at the end of the treatment course allowed a similar rate of success 
in both arms.  
 
In a similar way, the StiL group performed a phase III study that compared six 
cycles of BR and fludarabine-rituximab in 208 patients with relapsed/refractory 
iNHL or MCL. BR showed a superior efficacy, with a better ORR (83.5% 
versus 52.5%), CR (38.5% versus 16.2%) and PFS (30 versus 11 months), 
without any difference in terms of toxicity. 
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Since bentamustine in an alkylating agent, a great deal of attention has been 
focused in the issue of secondary malignancies. To date, the two StiL studies 
did not show an increased rate of MDS/AML or solid tumors in the BR arm; 
however, a longer follow up is still warranted to draw definitive conclusions.  
 
For the future directions, bendamustine is now being evaluated in 
relapsed/refractory iNHL in conjunction with a great variety of other agents 
(i.e. IMIDs, proteasome inhibitors, monoclonal antibodies [mAbs]). [4] 
 
Agents that target the cell surface: 
Novel mAb anti CD-20 
As mentioned previously, the introduction of the chimeric human-mouse mAb 
anti CD-20 rituximab actually changed the outcome of B-cell NHL and the 
combination of rituximab and chemotherapy is now the standard treatment 
inNHL. Nevertheless, a significant number of patients affected by iNHL 
develop recurrent disease and become refractory to first or subsequent 
immunochemotherapy treatment. In these cases retreatment with rituximab-
based therapy is not considered useful and new agents potentially able to 
overcome rituximab-resistance mechanisms are recommended. For this reason, 
several novel mAbs, either directed against CD20 or other antigens, were 
specifically designed by incorporating structural modifications that are hoped 
to overcome mechanisms of rituximab resistance. Many of these new mAbs are 
currently under different preclinical and clinical phases of assessment.  
 
Ofatumumab 
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Ofatumumab is a fully humanized anti-CD20 mAb. Classified as a type I mAb, 
ofatumumab displays greater complement-dependent cytotoxicity (CDC) with 
respect to rituximab [Telling et al. 2004]. Ofatumumab binds to a novel epitope 
of CD20, which encompasses the small extracellular loop and the N-terminal 
region of the second large extracellular loop. Ofatumumab binds to the CD20 
with greater avidity than rituximab and his action is carried out even at lower 
density of this cell surface antigen.  
 
In the field of iNHL, Ofatumumab has been initially tested in FL. In the first 
phase I/II study, Hagenbeek and coworkers enrolled 40 patients (37.5% 
previously treated with rituximab) affected by relapsed or refractory FL. The 
best response rate across all dose groups was 43%, without direct correlation 
with ofatumumab dose. Previous rituximab-treated patients had a response rate 
of 64%. The median time to progression  (TTP) was 8.8 months for all patients 
and 32.6 months for responders, with median DOR of 29.9 months. 
Ofatumumab was generally well tolerated and toxicity was similar to that of 
rituximab  (reversible grade 3-4 infusional reactions occurring during first 
infusion). Immunological tests showed that ofatumumab induced a longer 
lasting depletion of B cells (6-10 months) compared with rituximab. 
However,infections were infrequent and generally mild (18 grade 1-2 and 2 
grade 3).  
 
To assess whether this novel anti CD20 mAb might overcome rituximab 
resistance, ofatumumab was tested in 116 rituximab-refractory FL patients in a 
double-blind study evaluating two dose levels. Patients were heavily 
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pretreated: 65% had chemotherapy-refractory disease and the median number 
of previous treatments was 4. The subjects who received the higher dose 
experienced an ORR of 10% (1 CR, 8 PR) while 50% had stable disease (SD). 
Median DOR was 6 months. The limited activity in this setting suggests it 
should be combined with chemotherapy (CHOP or bendamustine). 
 
A subsequent phase II study explored the combination of ofatumumab with 
CHOP in 58 patients with previously untreated FL. In the higher dose group 
ORR was 100% (CR 38%). The most common grade 3-4 adverse events were 
leukopenia and neutropenia.  
In conclusion, ofatumumab has demonstrated efficacy as a single agent in 
relapsed/refractory FL patients, with less evident effect in true rituxmab 
refractory patients. The combination of ofatumumab and CHOP appears highly 
active in previously untreated FL and opens the way to further studies. 
 
Obinutuzumab (GA-101) 
Obinutuzumab (GA-101) is a third-generation, fully humanized, type II anti-
CD20 mAb, that was glyco-engineered to display afucosylated Fc region 
carbohydrates, resulting in enhanced antibody-dependent cell-mediated 
cytotoxicity (ADCC) activity and superior direct B-cell killing compared with 
rituximab and other type I mAbs, despite lower complement-dependent 
cytotoxicity (CDC) activity. GA-101 was investigated as a single agent in two 
phase I studies. In the first trial, 21 patients with relapsed/refractory B-cell 
NHL were treated with escalating doses of GA-101. All patients were heavily 
pretreated; 20 (95%) were previously exposed to rituximab and 9 (43%) were 
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rituximab-refractory. No dose-limiting toxicity was observed, and side-effects 
consisted primarily of grade 1-2 infusion- related reactions. An overall 
response was observed in nine patients (43%), including five CR/CRu. All 
responding patients belonged to the FL subgroup (ORR 69%, CR 38%). The 
phase II part of this study compared two different does of GA-101 in 40 
patients with relapsed/refractory FL. Better results were obtained in the higher 
dose group (ORR 60%, CR/CRu 33%; median PFS 11.8 months). These 
preliminary data indicate that GA-101 monotherapy display encouraging 
efficacy with higher response observed at higher dose. In the second phase I 
trial, 22 subjects with B-cell NHL or chronic lymphocytic leukemia (CLL) 
received four weekly does followed by maintenance therapy. Half of patients 
were refractory to prior rituximab. Toxicity was similar to the previous trial. 
After completion of induction, 5 patients obtained a PR (22%) and 12 had SD; 
8 patients received maintenance treatment, that lead to improvement of 
response in 3 patients. In the subset of FL, the best ORR was 40% (4/10 
including 1 CR). [4] 
 
Preliminary results of the first head-to-head trial of obinutuzumab against 
rituximab in relapsed/refractory iNHL patients have been presented at the last 
ASH meeting in San Diego (2011) and updated at the last EHA meeting in 
Amsterdam (2012). A total of 175 patients were randomized to recive four 
weekly infusions of either GA-101 or rituximab. Patients had received a 
median a median of two prior treatments (prior rituximab in 99). Safety 
analysis did not reveal any difference between the two treatments. Based on 
blinded central radiology review, ORR was significantly in favour of GA-101 
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(44.6% versus 26.7%); however, at the time of analyses (median observation 
time: 15 months), PFS and OS were not different between the two arms. 
Longer follow up is probably needed to establish whether the higher response 
rate of GA-101 with respect to rituximab could be able to translate also in 
better survival.  
Given its encouraging  antilymphoma activity, particularly in FL, 
obinutuzumab has been evaluated also in combination with chemotherapy in 
relapse/refractory FL setting. In a phase I study (GAUDI), 56 patients were 
randomized to receive either 6-8 CHOP or 4-6 FC cycles, in combination with 
GA-101. All patients (28/28) in the G-CHOP arm and 22/28 in the G-FC arm 
completed the treatment. Grade 3-4 neutropenia was reported in 39% and 50% 
of patients treated with G-CHOP and G-FC, respectively. ORR at the end of 
induction was 96.4% in G-CHOP group (39% CR) and 92.9% in G-FC group 
(50% CR). The response rate with G-CHOP compared favourably with the R-
CHOP arm of a similar previous trial (EORTC 20981). In conclusion GA-101 
can be combined safely with CHOP, demonstrating a high level of activity 
compared with historical controls, while G-FC showed worse tolerability. 
Following these promising results, obinutuzumab is currently being explored 
with chemotherapy (CHOP, CVP or bentamustine) as first-line therapy in a 
randomized phase III study against the current standard of care rituximab 
chemotherapy in patients eith advanced untreated iNHL. 
 
Antibodies against target other than CD20 
CD22 is an antigen widely expressed on normal and malignant B cells and 
plays a role in B cell receptor (BCR) activation and signal transduction.  
53 
 
Epratuzumab is a humanized anti-CD22 antibody that demonstrated ADCC 
and direct cytotoxicity in preclinical studies [Leonard et al. 2005]. Phase I/II 
studies showed that epratuzumab is well tolerated, and has significant single-
agent clinical activity across various dose levels in relapse/refractory FL, 
suggesting its combination with rituximab should be explored. In the 
relapse/refractory setting this combination demonstrated promising results, 
with an ORR of 54% in FL patients (CR 24%) and a media DOR of 13.4 
months. Also in first-line setting this regimen seems to be quite effective, 
showing an ORR of 84% (CR 33.3%) in 57 FL patients. 
Galiximab is a Chimeric human-primate anti-CD80 mAb with single-agent 
activity and excellent tolerability in previous treated FL. Aphase I/II study 
evaluating the combination of galiximab and rituximab in patients with 
relapsed/refractory FL showed an ORR of 66% and a median PFS of 12.1 
months. In 61 untreated FL patients, this regimen appeared efficacious (ORR 
72%, CR/CRu 47%), particularly in patients with low-risk Follicular 
Lymphoma International Prognostic Index (FLIPI) score (ORR 92%, CR/CRu 
75%, 75% 3-year PFS 75%). 
 
Immunoconjugates 
Another mechanism to induce cell killing beyond the direct antibody effect is 
represented by the use of a toxin conjugated to B-cell mAbs. Differently from 
naked antibodies, which exert their effects largely from the cell surface, 
conjugated antibodies often benefit from internalization. Inotuzumab 
ozigamicin (CMC-544) is a humanized anti-CD22 antibody conjugated to 
calicheamicin. In a phase I study the main toxicities included 
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thrombocytopenia, asthenia, nausea, neutropenia and elevated aspartate 
transaminase (AST). The ORR for all patients was 39%; 68% of patients with 
FL responded at the maximum tolerated dose. A phase II study evaluating the 
combination of inotuzumab ozigamicin and rituximab enrolled 110 patients 
with refractory or recurrent FL or aggressive NHL.In 38 patients with FL, ORR 
was 87%and median PFS was 23.6 months.  
 
Bispecific antibodies. 
Bispecific antibodies are antibodies that target two antigens. Blinatumomab is 
an anti-CD3/anti-CD19 antibody that engages cytotoxic T cells and malignant 
B cells, enhancing tumor lysis. Phase I studies have demonstrated tolerability 
and clinical activity in B-cell NHL. Further studies are now evaluating this 
promising new treatment in different NHL subtypes. 
 
Agents that target intercellular processes 
Proteasome inhibitors 
Bortezomib 
Bortezomib is a first-in-class drug designed to target the ubiquitin-proteasome 
complex; i.e. the regulatory pathway that exerts intracellular protein 
degradation in eukaryotes, resulting in impairment of apoptosis, that is 
considered one of the most involved pathways in the pathogenesis of iNHL. 
For this reason bortezomib has been evaluated with great interest in FL and 
iNFL (especially WM). 
Early phase II trials revealed striking variation of efficacy in different 
histologies: while significant response rates bortezomib were shown in MCL. 
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The results in other iNHLs were less impressive. The first trial addressing the 
efficacy of biweekly (biw) single-agent bortezomib at standard dose (1.3 
mg/mq) in FL showed dismal results, with a median TTP of 5.1 months. Best 
response rates were found with higher dose (1.5 mg/mq) in 18 patients with 
FL, with 50% ORR (22% CR), similar to the MCL group; however, the 
toxicity of this schedule, mainly in terms of grade 3-4 periferal neuropathy 
(PN) (8%) and thrombocytopenia (27%) was not negligible and led to frug 
discontinuation in 33% of subjects. In order to ameliorate toxicity, a weekly 
(qw) bortezomib schedule (1.8 mg/mq) was studied in 26 iNHL patients; 
however, the ORR was low (18%)and PFS was not improved (6.7 months). 
The weekly vs twice-weekly debate was answered by the GELA in a  
randomized phase II trial comparing to the two schedules of single-agent 
bortezomib in 87 relapsed/refractory FL patients. At planned interim analysis 
the weekly dosing arm demonstrated insufficient responses (ORR 23% vs 
32%) and twice-weekly schedule was recommended for furthers studies. 
However, given the unsatisfactory response rates of single-agent bortezomib, 
the focus moved to the combination of bortezomib with rituximab or 
immunochemotherapy regimens in the hope of improving efficacy in FL and 
iNFL. 
The combination of bortezomib and rituximab is an attractive area of 
investigation because of the different mechanism of action and side-effect 
profiles; moreover, in vitro and in vivo murine studies showed synergistic 
activity. One of the first studies addressing this combination explored again the 
weekly versus twice-weekly bortezomib schedule with the association of 
rituximab in 81 patients with relapsed/refractory FL or MZL. As expected, the 
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weekly schedule was better tolerated (grade 3-4 PN 5% versus 10%) and given 
the non inferiority in terms of efficacy, it was chosen for further develpoment. 
To this purpose, a large international randomized phase III trial (LYM-300) 
allocated 676 patients with relapsed/refectory FL to receive rituximab either 
alone or with bortezomib. Median PFS was 12.8 months in the bortezomib-
rituximab arm and 11 months in the rituximab only arm; this also coincided 
with a better ORR (63% versus 49%). However, the clinical benefit did not 
reach the anticipates prespecified improvement af 33% in PFS and the safety 
profile revealed higher rates of PN in a combination arm. Another phase II trial 
(BRIL-06) evaluating rituximaband bortezomib combination in 49 patients 
with relapsed/refractory iNFL and MCL, showed encourraging results: ORR 
53% (CR, 26.5%), 1-year PFS 50% for MZL and 37% for LPL. 
Many studies addressing feasibility and efficacy adding bertozemib to an 
immunochemotherapy regimen in iNHL patients have been performed in 
recent years. In a randomized phase II trial of the GELA, patients with B-cell 
NHL were allocated to receive frontline standard R-CHOP with addition of 
bortezomib either with the biweekly or weekly schedule. A total of 49 patients 
were enrolled, with a CR/CRu rate of 82%. The ORR appeared higher in the 
biweekly arm (90% versus 70%) and at the higher doses. However, since grade 
3 neurologic toxicity was excessively increased at the higher doses in both 
arms, the investigators concluded that the biweekly doses of bortezomib in 
combination with R-CHOP should not exceed 1 mg/mq. A recent phase I trial 
in untreated iNHL demonstrated, however, that weekly bortezomib, combined 
with modified R-CHOP with vincristine capped at 1.5 mg, is able to produce 
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high response rates without substantial increase in PN development (grade 3-4: 
11%) up to the maximum tolerated dose of 1.6 mg/mq. 
Recently, two phase II trials investigating the combination of bortezomib, 
bentamustine, and rituximab (VBR) have been completed. In the larger 
VERTICAL trial, 73 patients with relapsed/refractory FL were enrolled to 
receive up to five cycles of VBR. The ORR was 88% (53% CR) and the 
median PFS was 14.9 months. Myelosuppression was the main toxicity (25% 
and 14% of patients experienced 3-4 neutropenia and thrombocytopenia, 
respecively), while transient grade 3-4 neuropathy occurred in 11% of patients. 
Although the primary endpoint of CR >60% was not accomplished, this 
regimen demonstrated to be effective in this highly pretreated population. The 
second study (31 patients) showed comparable results: although ORR was 
encouraging (83% for all subtypes; 93% for FL), the 2-year PFS of 47% did 
not meet the primary endpoint of 25% improvement with respect to historical 
results of bendamustine-rituximab only. In conclusion, neither of these trials 
demonstrated a significant improvement in ORR and PFS with the addition of 
bortezomib in relapsed/refractory FL and other iNHL. 
As preclinical studies suggested that bortezomib, through inhibition of NF-kB, 
may act as a radio-sensitizer, a phase I study was designed to explore the 
feasibility of weekly bortezomib combined with radioimmunotherapy (90Y 
ibritumomab tiuxetan) in relapse/refractory FL: despite the high rate of 
hematologic toxicities, this regimen resulted safe, well tolerated and effective. 
Combination regimen including bortezomib seem to be an attractive option in 
WM. Recently, Treon and colleagues reported efficacy of bortezomib, 
dexametasone, and rituximab in 23 previously untreatede patients with 
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symptomatic WM. As a best response, median bone marrow disease 
involvement declines from 55% to 10%, serum IgM levels declined from 4830 
to 1115 mg/dl, and haematocrit increased from 29.8% to 38.2%. The ORR was 
96%, and at a median follow up of 22.8 months, 18 out of 23 patients remained 
free of disease  progression. The most common toxicity was PN, which led to 
discontinuation of treatment in 61% of patients. [4] 
 
Other proteasome inhibitors  
Bortezomib is a reversible proteasome inhibitor that exhibits a lower affinity to 
target-binding sites, resulting in practical limitation because of drug schedule 
and intensity. Carfilzomib is a second-generation irreversible and selective 
proteasome inhibitor: recent data showed that carfilzomib is highly active in 
relapsed/refractory MM patients, especially if bortezomib-naive. Notably this 
agent is associated with only minimal painful PN, while its dose-limiting 
toxicity is myelosuppression. Moreover recent data provided evidence of 
significant preclinical activity of carfilzomib in WM. 
 
mTOR inhibitors 
The PI3K/AKT/mTOR signalling pathway is one of the most deregulated in 
human cancer and it has been extensively studied as a molecular target in NHL 
therapy. This pathway regulates cell growth and survival in response to growth 
factor receptor signalling and metabolic status. The activation af AKT through 
PI3KT leads to the stimulation of the mammalian target of rapamycin (mTOR) 
that is a serine/threonine kinase that regulates translation of proteins involved 
in cell growth, protein synthesis and cell cycle progression; mTOR exerts its 
59 
 
action as a part of two complexes, mTORC1 and mTORC2, involved in the 
translation of oncogenes such as c-MYC or Cyclin D1.  
PI3K/AKT/mTOR activation has been described mainly in MCL; however, 
preclinical studies have also demonstrated activaion of mTOR pathways in 
indolent lymphomas such as FL and WM. For these reasons, many drugs 
targeting PI3K/AKT/mTOR pathways, and in particular rapamycin-analogue 
(rapalog) mTOR inhibitors, are under investigation in iNHL treatment. 
Rapamycin is a macrolide antibiotic that exerts its activity on mTORC1 
complex causing a conformational change in its activity site. New molecules 
with improved bioavailability are temsirolimus and everolimus. 
Temsirolimus. 
Temsirolimus is a water soluble rapalog that is rapidly converted to the parent 
compound rapamycin after intravenous administration. It has been mainly 
studies in MCL for which is now a treatment option in relapsed/refractory 
disease. 
Temsirolimus has been evaluated also in other NHL histotypes: Smith and 
colleagues published a phase II trial in which temsirolimus was used as a single 
agent in patients with relapsed aggressive and indolent lymphomas. FL patients 
reached on ORR and a CR rate of 54% and 26%, respectively, and median PFS 
of 12.7 months; median OS has not yet been reached; CLL/SLL, and other 
iNHL patients obtained a PR rate of 11% with no complete responders. If we 
consider the results obtained by Hess and colleagues in MCL (ORR 22%; 
median PFS 4.8 months), the results in FL seem promising. This was the first 
study to establish single-agent activity of temsirolimus in patients with B-cell 
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lymphomas other than MCL, showing that mTOR inhibition is a rational target 
also in other subtypes of lymphomas. 
 
Everolimus 
Everolimus, an orally available ester derivative of rapamycin, has been tested 
in a phase I study in advanced haematologic malignancies by Yee and 
colleagues: no dose-limiting toxicities were observed and although no 
objective response were observed in lymphoid malignancies, four or six 
patients with CLL had a reduction in lymphocytosis or lymphadenopathy. A 
recently Japanese phase I study evaluating everolimus in relapsed or refractory 
NHL confirmed no dose-limiting toxicities. Witzig and colleagues recently 
published a phase II study in which everolimus was tested in relapsed 
lymphoma, with an ORR of 30% with no major differences between  DLBCL, 
MCL and FL. In relapsed/refractory WM, Ghobrial and colleagues 
demonstrated an ORR of 70% (42% PR). 
 
In conclusion, rapalogs show a certain degree of activity in relapsed/refractory 
NHL; however, with the exception of WM, a relatively low percentage of 
complete and durable responses has been reported. For these reasons, new 
mTOR inhibitor molecules are under evaluation and in particular the 
association with other classes of drugs is warranted to increase their efficacy.  
 
CAL-101. The PI3K/AKT/mTOR pathway is essential in the survival of 
several different B-cell NHLs and therefore represents an attractive therapeutic 
target. The most important member in upstream part of this pathway is the 
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p110d isoform of PI3K, which is restricted to to cells of haematopoietic origin. 
CAL-101 is an oral potent p110d-selective PI3K inhibitor. Kahl and colleagues 
reported a phase I trial with this agent in 56 patients with an ORR of 62%. 
Notably, the most important dose-limiting toxicity was represented by 
reversible abnormalities in transaminases (33%). Further studies are planned 
for combinations of this with other agents including rituximab and 
bendamustine. [4] 
 
BTK inhibitors 
Burton's tyrosine kinase (BTK) is a key component of the BCR signalling 
pathway. The orally bioavailable compound PCI-32765 is a selective and 
permanent inhibitor of BTK, resulting in block of BCR-stimulated activation of 
NF-kB and ERK, inhibition of growth and induction of apoptosis of B cells. 
Fowler and colleagues presented the results of an ongoing phase I trial of PCI-
32765 in relapse/refractory B-cell malignancies. In 35 patients with iNHL, 
ORR was 40% (1 CR and 13 PR) and responses weredetected across all 
histologic subtypes and were quite durable.Side-effects were mild, with few 
grade 3 (9/47) and no grade 4 toxicities at this point in the dose escalation. 
 
BCL-2 inhibitors 
The Bcl-2 family is a group of proteins that may be either anti-apoptotic (e.g. 
Bcl-2, Bcl-X) or pro-apoptotic (Bax, Bak). The t(14;18), which occurs in 
majority of FL, results in the juxta-position of the BCL-2 gene next to the 
immunoglobulin heavy chain gene, leading to its constitutive expression and to 
signalling unbalance in favor of survival of malignant cells. AT-101, an orally 
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active Bcl-2 inhibitor, demonstrated some activity in patients with CLL, but 
was associated with dose-limiting hepatic and gastrointestinal toxicity. The 
orally available Bcl-Xl-inhibitor ABT-263 showed activity primarily in CLL, 
with thrombocytopenia being the main toxicity. Obatoclax is a novel Bcl-2 
inhibitor that appear to sensitize rituximab-resistant lymphoma cells to 
treatment with bortezomib; this agent is currently undergoing clinical 
investigation in combination with other agents in FL. 
 
Agents that target the microenvironment 
 
Lenalidomide 
Lenalidomide is an immunomodulatory drug (IMiD) which is 10,000 times 
more potent and displays a better safety profile than its parent compound 
thalidomide. The key to the therapeutic potential of lenalidomide lies in the 
fact that it has multiple mechanisms of action, resulting in anti-inflammatory, 
anti-angiogenic, and antitumor effects in a wide spectrum of hematological 
malignancies, such as myelodisplastic syndromes, multiple myeloma (MM) 
and B-cell NHL. To date, linalidomide has been associated with TNF-alfa 
inhibitory, T-cell costimulatory and anti-angiogenic effects. With respect to 
thalidomide, lenalidomide displays single-agent better efficacy, has a better 
safety profile and does not cause significant somnolence, constipation or 
peripheral neuropathy. However, myelosuppression can be a serious problem, 
and frequently a reduction of doses and/or granulocyte growth factor support is 
required. Both lenalidomide and thalidomide have comparable incidences of 
venous thrombotic disease (deep vein thrombosis or pulmonary embolism). 
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Lenalidomide has shown promising results in the tratment of patients with 
NHL. In a perspective phase II study evaluating the safety and the efficacy of 
lenalidomide monotherapy in 43 patients with relapsed/refractory iNHL the 
ORR was only 23% (3 CR and 7 PR); however responses were quite durable 
(more than 16 months). The median time of antitumor response was 3.6 months 
and the median PFS for the whole group was 4.4 months. Adverse events were 
predictable and manageable; the most common grade 3-4 adverse events were 
neutropenia (46%) and thrombocytopenia (19%).  
Based on preclinical studies demonstrating synergistic activity between 
rituximab and linalidomide in lymphoma models, several investigators are 
evaluating the efficacy and the tolerability of lenalidomide in combination with 
rituximab in iNHL. Results of a randomized CALGB study, evaluating 
lenalidomide alone versus lenalidomide and rituximab (RR or R2 regimen) in 
94 patients with recurrent FL (previously exposed to rituximab), were 
presented at the last ASCO meeting (2012). Briefly, RR was more active than 
lenalidomide alone and demonstrate significantly longer EFS, with similar 
hematologic toxicity. Recently, Fowler and colleagues reported the preliminary 
results of treatment with RR in newly diagnosed iNHL patients (n = 48; 30 
FL). The ORR was 86% for the entire cohort (CR 79%) and 93% for FL 
patients (CR 86%). At a median follow up of 20 months PFS was 91%. 
Adverse events were similar to those observed in lenalidomide single-agent 
studies. Of interest, no significant tumor-flare reactions were observed. Results 
of currently ongoing randomized trial evaluating the activity of this 
chemotherapy-free regimen in comparison with the current standard 
immunochemotherapy in iNHL are eagerly awaited. [4] 
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Aim 
The main purpose of this work was understanding how to treat Splenic 
Marginal Zone Lymphoma (SMZL) in patients unfit for surgery or more 
aggressive therapies. 
Methods 
30 newly diagnosed SMZL patients were included in this analysis.  
We enrolled all cases, consecutively treated in our Institution, not eligible for 
Rituximab-Cladribrine regimen or more toxic schedules because of 
comorbidity or previous serious infective episodes. 
Eligibility criteria were: histological diagnosis of SMZL, age >18 years, HIV 
negativity, two or more signs of active disease (symptomatic splenomegaly,  
constitutional symptoms , severe peripheral cytopenias); written informed 
consent. 
Patient evaluation included a full history and clinical examination, complete 
serum biochemistry with dosage of LDH and β2microglubulin, peripheral 
blood and bone marrow immunophenotyping, bone marrow biopsy, bone 
marrow molecular analysis, chest and abdomen and pelvic computed 
tomographic (CT) scan, serology for HIV, HBV and HCV. 
Diagnosis was based on lymphocyte morphology, immunophenotype of 
peripheral blood and bone marrow samples, bone marrow biopsy and spleen 
histology when available. 
Patients’clinical characteristics are shown in Table 1. One case was HCV-
positive. 
65 
 
According to IIL prognostic index, 11 patients resulted in low-risk group, 10 
patients in the intermediate group and 9 cases in the high risk group. 
Sex  Male: 20 Female: 
10 
Total: 30 
     
Median Age           70 years (range 59‐82) 
   
ECOG at diagnosis  Numbers of patients
0 8     
1 8     
2 14     
3, 4, 5 0     
Median LDH at diagnosis  321 U/L (range 143 U/L‐704 U/L) 
     
Median Hb at diagnosis  10,7 gr/dL (range 7,2gr/dL ‐15,4 gr/dL) 
     
Median Albumine at diagnosis  4,069 gr/dL (range 4,89gr/dL ‐2,68 gr/dL) 
     
Stage                                       Numbers of patients 
I 3    
II 2    
III 1    
IV 23    
Not Avialable 1    
IPI  Numbers of patients 
0 0    
1 5    
2 12    
3 11    
4 0    
5 0    
Not Avialable 2    
IIL score prognostic inedx  Numbers of patients 
Low 11    
Int 10    
High 9    
     
Toxicity                                       Numbers of patients 
Grade I anemia 3  
Grade I neutropenia 1  
Tab. 1 
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Treatment 
Cyclophosphamide was assumed at a dose of 100 mg per day for 15 
consecutive days. Cycles were repeated every 30 days for a total of six cycles. 
Rituximab was administered iv at a dose of 375 mg/m2 on day 8 of each cycle. 
Rituximab was infused over a 3-6 hour period, on an outpatient basis. Patients 
were pre-medicated with diphenhydramine (40 mg orally) and acetominophen 
(1 g orally). 
Patients were evaluated for response 2 months after the end of treatment, then 
every 3 months during the first 2 years and every 6 months for further 3 years. 
Bone marrow samples and bone marrow biopsy were performed in all patients 
at the end of therapy. 
Response to therapy was evaluated according to Cheson revised criteria (2007). 
CTCAE v.4 criteria were used to assess toxicity. 
 
Statistical analyses 
All calculations were performed using the SPSS for Windows, release 21, 
2012. Overall survival and time to progression (PFS) were estimated using the 
Kaplan-Meier test. PFS as computed from the beginning of treatment to further 
disease progression, relapse or death.  
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Results 
Between October 2005 and October 2012,  30 patients (20 male and 10 female; 
median age 70 years, range 51-83) with newly diagnosed SMZL were enrolled 
in this study.  
All patients were evaluable for clinical response. Overall response rate (ORR) 
was 87%: 21/30 (70%) achieved a complete hematological response (CR), 5/30 
(17%) a partial response (PR), and 4/30 (13%) resulted unresponsive.   
The median reduction of spleen size was 4 cm (range, 3-6 cm) among the cases 
that achieved a CR. 
 
After a median follow-up was 25 months (range 6-67), 2 out of 26 responsive 
cases relapsed with a median PFS of 20 months (range, 1-53). 
IIL prognostic index score influenced significantly PFS with a better outcome 
for low risk patients as  demonstrated by PFS Kaplan Maier curves (no 
censored data were observed in low risk patients  curve) and log-rank test of 
Mantel-Cox ( P=0.025): median PFS was 24 months and 19 months 
respectively for low-risk group and intermediate/high risk one (fig.1). 
All patients were evaluable for toxicity. Globally, this regimen was well 
tolerated and it was not necessary nor discontinue therapy or delay it in any 
case. Infectious events were not recorded. Haematological toxicity was mild 
(neutropenia or anemia of grade I). 
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Fig.1: IIL prognostic index score influenced significantly PFS with a better 
outcome for low risk patients (no censored data were observed in low risk 
patients  curve): median PFS was 24 months and 19 months respectively for 
low-risk group and intermediate/high risk one (P=0,025). 
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Discussion 
Splenic marginal lymphoma usually presents as an indolent disease that 
generally affects  older patients, and that because of its clinical features often 
does not need to be treated [5-7]. 
Where symptoms appear , the choice of treatment depends on the clinical 
localization,  presence of comorbidities, performance status and age of  patient. 
The therapeutic approach (surgical, immunotherapy, immunochemotherapy) 
should be defined without forgetting that it is an “indolent” disease and that the 
quality of life, especially in very elderly patients, is one of the most important 
objective [8-10]. 
In this light, especially in cases not eligible for surgery, or in patients where the 
main purpose of the treatment is the control of the symptomatology and not an 
improvement of survival curves, the use of oral drugs, could be a valid choice. 
In this context, alkylating agents such as chlorambucil and cyclophosphamide 
seem to have an interest role [23].  
The advent of Rituximab has dramatically changed the outcome of all 
lymphomas, even of marginal histotypes [16]. To date there are many data 
demonstrating its efficacy as monotherapy and in combination in these kind of 
patients [16, 24-26]. 
The present study was designed with the aim to evaluate the activity of oral 
cyclophosphamide associated with rituximab as first line therapy in patients 
with SMZL unfit for more aggressive therapies. Thirty patients were evaluated.  
ORR resulted  87% . IIL score prognostic index evidenced better outcome for 
low score patients with median PFS of 24 months versus 19 months of high 
and intermediate risk ones (P =0,025). No significant adverse event were 
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recorded. Comparing these results with those obtained on 20 cases with similar 
clinical features treated with rituximab alone in our center ( unpublished data ) 
, there was an advantage in terms of percentage of responses (87% versus 63%) 
for the group treated with the combination Rituximab-oral cyclophosphamide. 
Therefore, this therapeutic approach has proven effective enough and with a 
good toxicity profile. The impact on quality of life was in fact minimal, 
ensuring in most cases a normal lifestyle. 
Based on these data, although the small cohort of patients, we believe that this 
schedule could be considered  in SMZL patients, requiring therapy but who 
cannot sustain approaches potentially more toxic. 
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